Anti-TNF Withdrawal in Inflammatory Bowel Disease.

about

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

Item

http://www.wikidata.org/entity/Q55421713

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

@en

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

@nl

type

Item

label

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

@en

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

@nl

prefLabel

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

@en

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

@nl

P1476

Anti-TNF Withdrawal in Inflammatory Bowel Disease.

@en

P2093

Joana Torres

http://www.w3.org/2001/XMLSchema#string

Marília Cravo

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the management of inflammatory bowel disease in adults

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis.

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

P304

153-161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPGE.2015.11.004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

P577

2016-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290805233

http://www.w3.org/2001/XMLSchema#string

P698

28868451

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

TNF

inflammatory bowel diseases

P932

5580146

http://www.w3.org/2001/XMLSchema#string